Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Drosten

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Plos One|February 6, 2026
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, et al.
Cancer Cell|February 4, 2018
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK SignalingManuel Sanclemente, Sarah Francoz, Laura Esteban-Burgos, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathwayMatthias Drosten, Eleanor Y M Sum, Carmen G Lechuga, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2021
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoformMarina Salmón, Guillem Paniagua, Carmen G Lechuga, et al.
Cancer Research|November 23, 2016
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory SequencesMatthias Drosten, Lucía Simón-Carrasco, Isabel Hernández-Porras, et al.
Cancer Discovery|February 28, 2018
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their PropertiesYijun Gao, Matthew T Chang, Daniel McKay, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2020
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomasLaura Esteban-Burgos, Haiyun Wang, Patricia Nieto, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2024
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumorsFernando Fernández-García, Ana Fernández-Rodríguez, Coral Fustero-Torre, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2025
Systemic <i>Kras</i> ablation disrupts myeloid cell homeostasis in adult miceElena Zamorano-Dominguez, Lucía Morales-Cacho, Rebeca Barrero, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Plos One|February 6, 2026
RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1Laura de-la-Puente-Ovejero, Ana Fernández-Rodríguez, Sarah Francoz, et al.
Cancer Cell|February 4, 2018
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK SignalingManuel Sanclemente, Sarah Francoz, Laura Esteban-Burgos, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 8, 2014
Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathwayMatthias Drosten, Eleanor Y M Sum, Carmen G Lechuga, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 24, 2021
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoformMarina Salmón, Guillem Paniagua, Carmen G Lechuga, et al.
Cancer Research|November 23, 2016
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory SequencesMatthias Drosten, Lucía Simón-Carrasco, Isabel Hernández-Porras, et al.
Cancer Discovery|February 28, 2018
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their PropertiesYijun Gao, Matthew T Chang, Daniel McKay, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 11, 2020
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomasLaura Esteban-Burgos, Haiyun Wang, Patricia Nieto, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 2024
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumorsFernando Fernández-García, Ana Fernández-Rodríguez, Coral Fustero-Torre, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 18, 2025
Systemic <i>Kras</i> ablation disrupts myeloid cell homeostasis in adult miceElena Zamorano-Dominguez, Lucía Morales-Cacho, Rebeca Barrero, et al.
Pageof 5